We develop monoclonal antibody therapies for the treatment of cancer. We focus on developing antibodies that specifically target cancer cells and activate the body’s immune system to destroy these tumor cells without toxic effects to healthy normal cells. Such antibodies are mass manufactured through the use of genetic engineering technology and prepared for administration to patients as cancer therapeutics.
Glypican3: A molecular target for hepatocellular carcinoma
Glypican3(GPC3) is a glycosylphosphatidylinositol(GPI) -anchored protein on the cell surface with a molecular wiehgt of 60kDa
Research & Development
Antibody Therapies
